Table 2. Cross neutralization efficiency (IC50 ug/ml) of h-CMP-V1cyc1 gp120 and BG505:SOSIP.664 selected scFv monoclonals.
| Viruses | Tier/Subtype | Origin | C11 | D11 | 1F6 |
|---|---|---|---|---|---|
| MuLV | >100 | >100 | >100 | ||
| 92RW020 | 2A | Rwanda | <0.09 | <0.09 | 37.3 |
| BG505 | 2A | USA | 34.8 | 49.8 | 31.8 |
| JRCSF | 1B | USA | 7.75 | 5.75 | >100 |
| SF162 | 1B | USA | 42.8 | <0.09 | 9.75 |
| BAL.01 | 1B | USA | >100 | >100 | >100 |
| QZ4589 | 2B | Trinidad | <0.09 | <0.09 | 52.3 |
| SC422661.8 | 2B | Trinidad | 22.8 | 29.3 | 69.8 |
| TRO11 | 2B | Italy | 4.25 | >100 | 7.25 |
| JRFL | 2B | USA | 32.3 | 7.25 | >100 |
| RHPA4259.7 | 2B | USA | 3.25 | 22.8 | 30.8 |
| REJO4541.67 | 2B | USA | 63.3 | 75.8 | 70.8 |
| WITO4160.33 | 2B | USA | >100 | >100 | >100 |
| CAAN5342.A2 | 2B | USA | >100 | 40.8 | 42.3 |
| AC10.0.29 | 2B | USA | >100 | 40.8 | 80.8 |
| THRO4156.18 | 2B | USA | >100 | 43.8 | >100 |
| 6535.3 | 2B | USA | >100 | >100 | >100 |
| PVO.4 | 3B | Italy | 42.3 | 39.3 | >100 |
| MW965.26 | 1C | Malawi | >100 | >100 | >100 |
| 25711-2.4 | 1C | India | 35.3 | 32.3 | 41.9 |
| 25710-2.43 | 1C | India | 78.3 | 37.8 | 50.3 |
| 16055-2.3 | 2C | India | 52.8 | 26.3 | >100 |
| 16936-2.21 | 2C | India | >100 | >100 | 25.6 |
| 001428-2.42 | 2C | India | 60.8 | 5.75 | 62.3 |
| AIIMS254 | 2C | India | >100 | 21.8 | 57.3 |
| AIIMS253 | nd | India | >100 | >100 | >100 |
| AIIMS212 | 2C | India | >100 | 50.3 | >100 |
| AIIMS201 | 2C | India | >100 | >100 | >100 |
| AIIMS65 | 2C | India | >100 | 24.3 | >100 |
| AIIMS126 | 2C | India | >100 | 29.3 | >100 |
| AIIMS70 | 2C | India | >100 | >100 | >100 |
| AIIMS 261 | 2C | India | 47.8 | 36.8 | >100 |
| AIIMS329 | 2C | India | 35.8 | 37.8 | >100 |
| AIIMS 346 | 2C | India | 15.6 | >100 | >100 |
| AIIMS 355 | 2C | India | 26.3 | 26.8 | >100 |
| AIIMS 504 | 2C | India | >100 | 35.3 | >100 |
| AIIMS 506 | 2C | India | >100 | >100 | >100 |
| AIIMS 511 | 2C | India | 37.8 | 39.8 | >100 |
| AIIMS 519 | 2C | India | 36.8 | 70.8 | >100 |
| AIIMS 529 | 2C | India | 41.8 | >100 | >100 |
| ZM53M.PB12 | 2C | Zambia | >100 | >100 | >100 |
| ZM233M.PB6 | 2C | Zambia | 46.3 | 38.8 | 40.8 |
| ZM249M.PL1 | 2C | Zambia | 55.8 | 48.3 | 81.3 |
| ZM135M.PL10a | 2C | Zambia | >100 | >100 | >100 |
| ZM214M.PL15 | 2C | Zambia | >100 | 48.8 | 46.3 |
| ZM109F.PB4 | 1C | Zambia | >100 | >100 | >100 |
| DU172.17 | 2C | South Africa | 63.3 | 29.8 | >100 |
| DU422.1 | 2C | South Africa | 12.3 | 4.75 | 4.75 |
| DU156.12 | 2C | South Africa | >100 | >100 | >100 |
| CAP210.2.00.E8 | 2C | South Africa | 76.8 | 49.8 | >100 |
| THA092.009 | E | Thailand | >100 | >100 | nd |
Neutralization profile of the three scFv monoclonals: scFv monoclonals were checked for their neutralizing efficiency with a standard panel of subtype_A, B and C pseudoviruses and primary isolates. scFv monoclonal fragments were tested at concentrations ranging from 0.09 μg/ml to 100 μg/ml. HEP scFv48 was taken as negative control for scFvs. MuLV was used as a negative control along with virus controls and cell controls. nd: not determined. Non-linear regression curve straight line was plotted using the method of least squares to determine the IC50 values.